- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03359096
Hypoglossal Nerve Stimulation on Cardiovascular Outcomes (CARDIOSA-12)
Cardiovascular Endpoints for Obstructive Sleep Apnea With Twelfth Nerve Stimulation (CARDIOSA-12): A Randomized, Sham-Controlled, Double-Blind, Crossover Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
All patients recruited into the study will have already been implanted with the Inspire® HGNS device.
Additional Inclusion Criteria include:
- As tolerating the therapeutic level during sleep can take time (weeks to months), all patients must be able to use the device at the therapeutic setting (> 20 hours/week for > 1 month) prior to enrollment, based on compliance data.
- All patients will be English-speaking and able to give written informed consent.
Exclusion Criteria include:
- Inspire® remote Model 2500 or later is required. Patients with older remotes are not candidates due to limited adherence monitoring capabilities.
- Patients who have fallen asleep while driving resulting in accident or "near miss" accident within 1 year prior to HGNS implantation.
- Actively using positive airway pressure (PAP) therapy for treatment of OSA.
- Patients in whom the difference between sham and therapeutic voltages is less than 30% the therapeutic voltage.
Pregnant women will be excluded.*
- Women of childbearing potential must NOT be pregnant or plan on becoming pregnant. This study involves temporarily stopping treatment of obstructive sleep apnea, which may harm the fetus. If applicable, the patient will need to take a urine pregnancy test after enrollment (prior to washout #1), and again prior to washout #2.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Therapeutic HGNS
Therapeutic Hypoglossal Nerve Stimulation (HGNS).
Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study.
|
Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve.
Patient will undergo activation of the implanted device one month post-operatively.
A functional threshold (in volts) is obtained based on tongue motion during device stimulation.
For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
Other Names:
|
Sham Comparator: Subtherapeutic 'Sham' HGNS
Sham threshold determination will be performed as follows.
The patient will be in a reclined position with the mouth open while nasal breathing.
Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion.
This process is repeated twice and the average value is used to determine "sham-HGNS".
The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds.
|
Sham threshold determination will be performed as follows.
The patient will be in a reclined position with the mouth open while nasal breathing.
Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion.
This process is repeated twice and the average value is used to determine "sham-HGNS".
The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean 24-Hour Systolic Ambulatory Blood Pressure Values
Time Frame: Study Week 6, Day 1; study Week 11, Day 1
|
Patients will undergo 24-hour ambulatory blood pressure testing (ABP) using a noninvasive, portable device.
The monitor is programmed to record blood pressure every 30 minutes.
The patient will be asked to record bedtime and wake time to corroborate the sleep and wake time from the recorder.
Mean 24-hour systolic ambulatory blood pressure values will be calculated.
|
Study Week 6, Day 1; study Week 11, Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean 24-Hour Diastolic Ambulatory Blood Pressure Values
Time Frame: Study Week 6, Day 1; study Week 11, Day 1
|
Patients will undergo 24-hour ambulatory blood pressure testing (ABP) using a noninvasive, portable device.
The monitor is programmed to record blood pressure every 30 minutes.
The patient will be asked to record bedtime and wake time to corroborate the sleep and wake time from the recorder.
Mean 24-hour diastolic ambulatory blood pressure values will be calculated.
|
Study Week 6, Day 1; study Week 11, Day 1
|
Mean Nocturnal Systolic and Diastolic Ambulatory Blood Pressure Values
Time Frame: Study Week 6, Day 1; study Week 11, Day 1
|
Patients will undergo ambulatory blood pressure testing (ABP) using a noninvasive, portable device.
The patient will be asked to record bedtime and wake time to corroborate the sleep and wake time from the recorder.
Mean sleep systolic and diastolic ambulatory blood pressure values will be calculated.
|
Study Week 6, Day 1; study Week 11, Day 1
|
Mean Muscle Sympathetic Nerve Activity (MSNA) Frequency (Bursts/Minute)
Time Frame: Study Week 6, Day 2; Study Week 11, Day 2
|
The peroneal nerve will be located with transcutaneous stimulation and a tungsten microelectrode will be inserted into the nerve, and a reference electrode will be inserted 1-2 cm from the recording electrode. Nerve signals will be preamplified, amplified, filtered, rectified, and integrated to obtain a mean voltage display of sympathetic nerve activity that is recorded. Muscle sympathetic bursts will be identified by visual inspection and expressed as burst frequency (bursts per minute). MSNA was only performed on 7 patients at Emory University, prior to the trial being transferred to the University of Pennsylvania. This is due to there being no research collaborators available at the University of Pennsylvania to capture MSNA as part of this trial. There is insufficient data gathered to make meaningful claims regarding this outcome measure. |
Study Week 6, Day 2; Study Week 11, Day 2
|
Mean Muscle Sympathetic Nerve Activity (MSNA) Tonal Activity (Units/Minute)
Time Frame: Study Week 6, Day 2; Study Week 11, Day 2
|
The peroneal nerve will be located with transcutaneous stimulation and a tungsten microelectrode will be inserted into the nerve, and a reference electrode will be inserted 1-2 cm from the recording electrode. Nerve signals will be preamplified, amplified, filtered, rectified, and integrated to obtain tonal activity (units/minute). MSNA was only performed on 7 patients at Emory University, prior to the trial being transferred to the University of Pennsylvania. This is due to there being no research collaborators available at the University of Pennsylvania to capture MSNA as part of this trial. There is insufficient data gathered to make meaningful claims regarding this outcome measure. |
Study Week 6, Day 2; Study Week 11, Day 2
|
Mean Pre-Ejection Period (PEP)
Time Frame: Study Week 6, Day 2; Study Week 11, Day 2
|
A patient will be fitted with Impedance Cardiography (ICG) Noninvasive Cardiac Output Module that will record the ECG (Electrocardiogram) and the ICG (Impedance cardiography) continuously during a 10-minute period.
PEP will be calculated as the average interval (milliseconds) from the onset of left ventricular depolarization, reflected by the Q-wave onset in the ECG to the opening of the aortic valve, reflected by the B-point in the ICG signal.
A significant difference in PEP to be a 10 millisecond increase from baseline.
|
Study Week 6, Day 2; Study Week 11, Day 2
|
Mean Flow-mediated Dilation (FMD)
Time Frame: Study Week 6, Day 2; Study Week 11, Day 2
|
The brachial artery of the nondominant arm will be imaged using a high-resolution ultrasound transducer.
A blood pressure cuff on the forearm will be inflated to suprasystolic pressures to produce 5 min of ischemia.
On cuff deflation, imaging will be performed to measure FMD.
Brachial artery FMD will be calculated as (post-ischemia diameter - baseline diameter) / (baseline diameter) x 100.
|
Study Week 6, Day 2; Study Week 11, Day 2
|
Mean Peripheral Arterial Stiffness (PAS)
Time Frame: Study Week 6, Day 2; Study Week 11, Day 2
|
Following a rest period of 10 minutes with subjects in a supine position in a quiet, temperature-controlled room, blood pressure will be measured 3 times at 5-minute intervals by an automatic device. The standard metric of peripheral arterial stiffness (PAS) is carotid-femoral pulse wave velocity (PWV), which will be estimated using the Sphygmocor device® (Atcor Medical, Sydney, Australia). PAS was only captured on 21 patients at Emory University and the University of Pennsylvania. This is due to our cardiovascular research collaborators at the University of Pennsylvania indicating they would no longer be able to support our research study due to their own COVID-19 related resource constraints. There is insufficient data gathered to make meaningful claims regarding this outcome measure. PAS is reported as changes in pulse wave velocity, with a meters/second unit measure. |
Study Week 6, Day 2; Study Week 11, Day 2
|
Mean Psychomotor Vigilance Test (PVT) Reciprocal Reaction Time
Time Frame: Study Week 6, Day 2; Study Week 11, Day 2
|
Patients will perform the neurobehavioral test on a specially calibrated (for timing precision) and designated laptop in a quiet room in the outpatient setting. Each patient will perform a unique version of the psychomotor vigilance test to assess psychomotor speed. The trial's protocol was amended to begin capturing neurobehavioral measures like the PVT at the University of Pennsylvania, as part of a new collaboration with research collaborators in the Department of Psychiatry. PVT is a validated instrument to capture attention, and response time on this cognitive test is reported as reciprocal milliseconds or 1/milliseconds. |
Study Week 6, Day 2; Study Week 11, Day 2
|
Mean Digit Symbol Substitution Test (DSST) Reaction Time
Time Frame: Study Week 6, Day 2; Study Week 11, Day 2
|
Patients will perform the neurobehavioral test on a specially calibrated (for timing precision) and designated laptop in a quiet room in the outpatient setting. Each patient will perform a unique version of the digit symbol substitution test to assess processing speed. The trial's protocol was amended to begin capturing neurobehavioral measures like the DSST at the University of Pennsylvania, as part of a new collaboration with research collaborators in the Department of Psychiatry. DSST is a validated instrument to capture visual tracking and working memory, and response time on this cognitive test is reported in milliseconds. |
Study Week 6, Day 2; Study Week 11, Day 2
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 834158
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
ResMedCompletedObstructive Sleep Apnea (OSA)United States, Australia
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
-
State Key Laboratory of Respiratory DiseaseCompletedObstructive Sleep Apnea of AdultChina
Clinical Trials on Therapeutic HGNS
-
Apnex Medical, Inc.CompletedObstructive Sleep ApneaUnited States
-
Apnex Medical, Inc.CompletedObstructive Sleep Apnea
-
University of ChicagoRecruitingObstructive Sleep ApneaUnited States
-
Emory UniversityTerminatedObstructive Sleep ApneaUnited States
-
Apnex Medical, Inc.TerminatedObstructive Sleep ApneaUnited States, Australia
-
Roy La Touche ArbizuUniversidad Autonoma de Madrid; Centro Universitario La Salle; Servicio Madrileño...UnknownLow Back Pain | Chronic Nonspecific Low Back PainSpain
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityEnrolling by invitationMalignant Solid Neoplasm | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III... and other conditionsUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingBladder CancerUnited States, Canada
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiac ArrestUnited States, Canada
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiac ArrestUnited States, Canada, United Kingdom